ProducedRaw
Bluelighter
- Joined
- Dec 2, 2006
- Messages
- 79
This paper states that during nicotine withdrawal, CRF-1 receptors are agonised and lead to increased stress levels which in turn lead to relapse:
I've found three CRF-1 antagonists - Antalarmin, CP-154,526 and Pexacerfont. Has anyone tried using these to combat nicotine withdrawal or am I going to have to be the guinea pig?
George et al. (3) report that (i) precipitated nicotine withdrawal in rats increases CRF levels in the central nucleus of the amygdala; (ii) precipitated withdrawal increases anxiety-like behavior through activation of CRF1 receptors; (iii) cessation of nicotine exposure in rats previously exposed to nicotine increases nicotine self-administration; and (iv) antagonism of CRF1 receptors prevents “abstinence”-induced increases in nicotine intake. This series of experiments provides strong support for the idea that CRF1 is involved in the biology and behavior of nicotine withdrawal, including negative reinforcement (i.e., offsetting the unpleasantness of cessation) and relapse (i.e., a return to self-administration). In other words, nicotine withdrawal is indeed a stressor that acts via the CRF–CRF1 system, which in turn results in increased nicotine self-administration to offset stress. This finding also suggests that pharmaceutical interventions should be developed to intervene in the stress system, to attenuate withdrawal-induced smoking relapse.
I've found three CRF-1 antagonists - Antalarmin, CP-154,526 and Pexacerfont. Has anyone tried using these to combat nicotine withdrawal or am I going to have to be the guinea pig?
